Cisplatin and Alternating Temozolomide in Recurrent High-Grade Gliomas: Efficacy and the Role of Tumor-Infiltrating Lymphocytes in a Phase II Clinical Trial
The cisplatin plus alternating TMZ regimen is feasible and safe for recurrent high-grade gliomas, with low CD8+ TILs potentially predicting favorable responses.
Authors
- Xiaojie Ding (ORCID: https://orcid.org/0009-0002-1863-8769)
- Yu Yao (ORCID: https://orcid.org/0000-0002-8366-4712)
- Chunxia Ji (ORCID: https://orcid.org/0000-0003-0700-7152)
- Haixia Cheng (ORCID: https://orcid.org/0000-0002-1601-8673)
- Di Chen (ORCID: https://orcid.org/0000-0002-9497-3588)
- Dikang Chen
- Zhenyu Zhang (ORCID: https://orcid.org/0000-0001-5570-090X)
- Ying Qi (ORCID: https://orcid.org/0009-0008-7649-6926)
- Jianbo Wen (ORCID: https://orcid.org/0000-0002-3269-2449)
- Chao Tang (ORCID: https://orcid.org/0000-0003-2524-8451)
- Lingchao Chen (ORCID: https://orcid.org/0009-0007-6658-9101)
- Yuyuan Wang
Institutions
- Fudan University (CN)
- Shanghai Clinical Research Center (CN)
- Huashan Hospital (CN)
- Shanghai Center for Brain Science and Brain-Inspired Technology (CN)
Publication Details
- Journal
- Clinical Medicine Insights Oncology
- Published
- 2025-07-13
- DOI
- https://doi.org/10.1177/11795549251350188
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63